SEC Company Response from MARINUS PHARMACEUTICALS, INC. (MRNS) (CIK 0001267813) — Jul 20, 2020
MARINUS PHARMACEUTICALS, INC. (MRNS) (CIK 0001267813)
Date: July 20, 2020 · CIK: 0001267813 · Accession: 0001104659-20-084948
AI Filing Summary & Sentiment
File numbers found in text: 333-239780
Letter
Marinus Pharmaceuticals, Inc.
5 Radnor Corporate Center, Suite 500
100 Matsonford Rd
Radnor, PA 19087
July 20, 2020
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Attn: Jeffrey Gabor
Re: Marinus Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed July 9, 2020
File No. 333-239780
Request for Acceleration of Effective Date
Ladies and Gentlemen:
On July 16, 2020, Marinus Pharmaceuticals, Inc. (the “Company”) requested acceleration of the effective date and time of the above-referenced Registration Statement on Form S-3 for Monday, July 20, 2020, at 4:00 PM, Eastern Time, or as soon as possible thereafter. The Company hereby withdraws such acceleration request until further notice.
Please feel free to direct any questions or comments concerning this request to Steve Abrams of Hogan Lovells US LLP at (267) 675-4671.
Very truly yours,
Marinus Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Marinus Pharmaceuticals, Inc.
5 Radnor Corporate Center, Suite 500
100 Matsonford Rd
Radnor, PA 19087
July 20, 2020
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Attn: Jeffrey Gabor
Re: Marinus Pharmaceuticals,
Inc.
Registration Statement on
Form S-3
Filed July 9, 2020
File No. 333-239780
Request for Acceleration
of Effective Date
Ladies and Gentlemen:
On July 16, 2020, Marinus Pharmaceuticals, Inc. (the “Company”)
requested acceleration of the effective date and time of the above-referenced Registration Statement on Form S-3 for Monday, July
20, 2020, at 4:00 PM, Eastern Time, or as soon as possible thereafter. The Company hereby withdraws such acceleration request until
further notice.
Please feel free to direct any questions or comments concerning
this request to Steve Abrams of Hogan Lovells US LLP at (267) 675-4671.
Very truly yours,
Marinus Pharmaceuticals, Inc.
/s/ Edward F. Smith
By:
Edward F. Smith
Title:
Vice President, Chief Financial Officer, Secretary and Treasurer